The recently published Prophylactic Antibiotic Regimens In Tumor Surgery (PARITY) trial found no benefit in extending antibiotic prophylaxis from 24 hours to five days after endoprosthetic reconstruction for lower limb bone tumours. PARITY is the first randomized controlled trial in orthopaedic oncology and is a huge step forward in understanding antibiotic prophylaxis. However, significant gaps remain, including questions around antibiotic choice, particularly in the UK, where cephalosporins are avoided due to concerns of Cite this article:
The diagnosis of periprosthetic joint infection can be difficult
due to the high rate of culture-negative infections. The aim of
this study was to assess the use of next-generation sequencing for
detecting organisms in synovial fluid. In this prospective, single-blinded study, 86 anonymized samples
of synovial fluid were obtained from patients undergoing aspiration
of the hip or knee as part of the investigation of a periprosthetic
infection. A panel of synovial fluid tests, including levels of
C-reactive protein, human neutrophil elastase, total neutrophil
count, alpha-defensin, and culture were performed prior to next-generation
sequencing.Aims
Materials and Methods
Previous standards for assessing the reliability
of a measurement tool have lacked consistency. We reviewed the most
current American Society for Testing and Materials and International
Organisation for Standardisation (ISO) recommendations, and propose
an algorithm for orthopaedic surgeons. When assessing a measurement
tool, conditions of the experimental set-up and clear formulae used
to compile the results should be strictly reported. According to
these recent guidelines, accuracy is a confusing word with an overly
broad meaning and should therefore be abandoned. Depending on the
experimental conditions, one should be referring to bias (when the study
protocol involves accepted reference values), and repeatability
(sr, r) or reproducibility (SR, R). In the absence of accepted reference
values, only repeatability (sr, r) or reproducibility (SR, R) should
be provided. Take home message: Assessing the reliability of a measurement
tool involves reporting bias, repeatability and/or reproducibility
depending on the defined conditions, instead of precision or accuracy. Cite this article:
Intravenous tranexamic acid (TXA) has been shown
to be effective in reducing blood loss and the need for transfusion
after joint replacement. Recently, there has been interest in applying
it topically before the closure of surgical wounds. This has the
advantages of ease of application, maximum concentration at the
site of bleeding, minimising its systemic absorption and, consequently,
concerns about possible side-effects. We conducted a systematic review and meta-analysis which included
14 randomised controlled trials (11 in knee replacement, two in
hip replacement and one in both) which investigated the effect of
topical TXA on blood loss and rates of transfusion. Topical TXA
significantly reduced the rate of blood transfusion (total knee
replacement: risk ratio (RR) 4.51; 95% confidence interval (CI):
3.02 to 6.72; p <
0.001 (nine trials, I2 = 0%); total
hip replacement: RR 2.56; 95% CI: 1.32 to 4.97, p = 0.004 (one trial)).
The rate of thromboembolic events with topical TXA were similar
to those found with a placebo. Indirect comparison of placebo-controlled
trials of topical and intravenous TXA indicates that topical administration
is superior to the intravenous route. In conclusion, topical TXA is an effective and safe method of
reducing the need for blood transfusion after total knee and hip
replacement. Further research is required to find its optimum dose
for topical use. Cite this article:
